The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASBO47, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

Compounds of the formula I ##STR1## useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

The invention relates to novel isoquinolines and their use as anticonvulsant and in the treatment of a variety of disorders.

Compounds of general formula I ##STR1## are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

The invention provides certain thiazolopyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases. ##STR1##

The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds. ##STR1##

Novel Inhibitors of Rho-kinases are disclosed.

This invention relates to newly identified ester-linked gemini surfactant compounds, to the use of such compounds and to their production. The invention also relates to the use of the ester-linked gemini surfactant compounds to facilitate the transfer of polynucleotides into cells.

A compound of formula (I) ##STR00001## wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R' is hydrogen, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.3 alkoxy; halogen, trifluoromethyl or OCH.sub.xF.sub.y, R'' is hydrogen, fluoro or chloro, that R'' being fluoro or chloro only when R' is fluoro or chloro; R.sub.3 is hydrogen or C.sub.1-C.sub.5 alkyl R.sub.4 is hydrogen, CH.sub.2OCOC(CH.sub.3).sub.3, pharmaceutically acceptable inorganic or organic cations, or COR.sub.4' wherein R.sub.4...